Is NCT05040360 recruiting in Fairbanks, AK?

Yes, NCT05040360 is currently recruiting participants at its Fairbanks, AK location. This pancreatic neuroendocrine tumors clinical trial is actively enrolling qualified participants.

Is participation in this Fairbanks clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Pancreatic Neuroendocrine Tumors Clinical Trial in Fairbanks, AK

Q: How do I join the pancreatic neuroendocrine tumors clinical trial in Fairbanks?

To join this clinical trial in Fairbanks, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Pancreatic Neuroendocrine Tumors Study in Fairbanks

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients wit

Sponsor: SWOG Cancer Research Network

Who Can Participate

Inclusion Criteria

Participants must have a histologic diagnosis of well-differentiated pancreatic neuroendocrine tumor (pNET) that was resected between 14 and 120 days prior to registration. Participants must have a scan within 90 days prior to registration without evidence of metastatic disease. Acceptable scans are multiphase computed tomography (CT) abdomen, magnetic resonance imaging (MRI) with intravenous (IV) contrast of the abdomen, or positron emission tomography (PET)-CT DOTATATE imaging if the DOTATATE PET-CT included IV iodine contrast for the CT portion of the exam

Resection must have been an R0 or R1 per treating investigator's assessment and/or pathology report

Ki-67 testing, which is considered part of standard of care in the pathology report, must have been performed between 14 and 90 days prior to registration and the result must be \>= 3% and =\< 55%. Treating investigators are encouraged to contact the S2104 Study Chairs and/or the study pathology chair with questions. If more than one Ki-67 is reported (e.g., primary tumor versus lymph node or metastatic site), the highest one should be considered for the study eligibility criteria

Participants with localized resected pNETS must have a Zaidi score of \>= 3 derived by the following factors and points:

1 point; symptomatic tumor defined as one of the following:

Gastrointestinal bleed

Gastrointestinal obstruction

Pain from primary tumor prior to surgical resection

Pancreatitis

2 points; primary pancreas tumor size \> 2 cm

1 point; Ki-67 3% to 20%

1 point; lymph node positivity = 1

6 points; Ki-67 21% to 55%

Participants may have received resection/ablation of liver oligo-metastatic disease (up to 5 liver metastases) at the time of well-differentiated pNET resection

Participants must have recovered from effects of surgery as determined by the treating investigator

Participants must be \>= 18 years old

Participants must have Zubrod performance status of 0-2

Participants must have a complete medical history and physical exam within 28 days prior to registration

Leukocytes \>= 3 x 10\^3/uL (within 28 days prior to registration)

Absolute neutrophil count \>= 1.5 x 10\^3/uL (within 28 days prior to registration)

Platelets \>= 100 x 10\^3/uL (within 28 days prior to registration)

Total bilirubin =\< institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to registration)

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x institutional ULN (within 28 days prior to registration)

Serum creatinine =\< 1.5 x institutional ULN (within 28 days prior to registration)

Calculated creatinine clearance \>= 50 ml/min (within 28 days prior to registration)

Participants must be able to swallow pills

Participants must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for their treatment and the protocol

No other active malignancy or history of prior malignancy is allowed, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years

Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Exclusion Criteria

Participants must not have unresected or unablated metastatic disease

Participants must not have clinically apparent central nervous system metastases or carcinomatous meningitis

Participants must not have received prior neoadjuvant therapy for treatment of pancreatic neuroendocrine tumor. Use of somatostatin analogs prior to surgery is permitted

Participants must not have received somatostatin analogs after surgery

Participants must not be planning to receive warfarin while on protocol treatment. Other anticoagulants are allowed

Participants must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or capecitabine

Participants must not have known absorption issues that would limit the ability to absorb study agents

Participants must not have had an arterial thromboembolic event, unstable angina, or myocardial infarction within 12 months prior to registration

Participants must not have active or uncontrolled infection

Participants must not have serious medical or psychiatric illness that could affect study participation in the judgement of the treating investigator

Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fairbanks?

Yes, this clinical trial (NCT05040360) has an active research site in Fairbanks, AK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Neuroendocrine Tumors Treatment Options in Fairbanks, AK

If you're searching for pancreatic neuroendocrine tumors treatment options in Fairbanks, AK, this clinical trial (NCT05040360) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fairbanks research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced pancreatic neuroendocrine tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic neuroendocrine tumors clinical trials near you to find additional studies recruiting in your area.

Pancreatic Neuroendocrine Tumors Clinical Trial in Fairbanks, AK

Expert Care in Fairbanks

IRB Approved

No-Cost Care

Apply for This Fairbanks Location

Why Participate?

Simple Process